Marketing Messages in Continuing Medical Education (CME) Modules on Binge-Eating Disorder (BED).
| Author | |
|---|---|
| Abstract |
:
In 2015, Vyvanse (lisdexamfetamine) became the first Food and Drug Administration (FDA)-approved treatment for binge-eating disorder (BED), a condition first recognized by the DSM-V in 2013. Because pharmaceutical companies use continuing medical education (CME) to help sell drugs, we explored possible bias in CME modules on BED. |
| Year of Publication |
:
1969
|
| Journal |
:
Journal of the American Board of Family Medicine : JABFM
|
| Volume |
:
33
|
| Issue |
:
2
|
| Number of Pages |
:
240-251
|
| Date Published |
:
1969
|
| ISSN Number |
:
1557-2625
|
| URL |
:
http://www.jabfm.org/cgi/pmidlookup?view=long&pmid=32179607
|
| DOI |
:
10.3122/jabfm.2020.02.190129
|
| Short Title |
:
J Am Board Fam Med
|
| Download citation |
